Intermediary

Crux Platform for Transferring Clean Energy Tax Credits Is Growing Rapidly with Hundreds of Millions of Dollars in Transactions in Process and Intermediary Partners Who Represent Billions in Annual Volume

Retrieved on: 
Tuesday, September 12, 2023
Chief commercial officer, Sellers, Multimedia, Stakeholder, Virtual CFO, Climate Week NYC, CFO, Ecosystem, Intermediary, Software, Cryptocurrency, Crux, Mobilize

NEW YORK, Sept. 12, 2023 /PRNewswire/ -- In advance of Climate Week, Crux, the ecosystem for transferable clean energy tax credits, announced that its platform is being used by developers, tax credit buyers, and intermediaries, with hundreds of millions of dollars in deals in process.

Key Points: 
  • On the Crux platform, intermediaries use branded portals to manage syndication of credits to existing clients and connect to new developers and credit buyers.
  • By convening buyers, sellers, and intermediaries around the same powerful software, Crux is building the deepest and most liquid market.
  • "Intermediaries will be critical to scaling the new multi hundred billion dollar market for transferable tax credits.
  • Crux is co-founded by Alfred Johnson and Allen Kramer, who previously founded and exited a successful marketplace software company, Mobilize.

Profound Medical Announces At-the-Market Offering of up to US$30,000,000

Retrieved on: 
Thursday, September 7, 2023
Standby Equity Distribution Agreement, Toronto Stock Exchange, Telephone, Peer-to-peer file sharing, Unit, EDGAR, Sale, Register, Agent, Offering, Intermediary, United States Army Medical Corps, Indian stock exchange, Form, TSX, Security (finance), Registration statement, Bank

The volume and timing of distributions under the ATM Program will be determined at the Company’s discretion.

Key Points: 
  • The volume and timing of distributions under the ATM Program will be determined at the Company’s discretion.
  • 333-263248) (the “Registration Statement”), filed with the U.S. Securities and Exchange Commission under the U.S. Securities Act of 1933, as amended.
  • The timing and extent of the use of the ATM Program will be at the discretion of the Company.
  • Copies of the Distribution Agreement, the Prospectus Supplement and the Base Shelf Prospectus are available on SEDAR+ at www.sedarplus.ca and the Distribution Agreement, the U.S.

Cybin Announces Renewed At-The-Market Equity Program of up to US$35 Million

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Mental Health, Alternative Medicine, Health, Pharmaceutical, Standby Equity Distribution Agreement, Treasury, Purchasing, Inc., NEO Exchange, Asset purchase agreement, University Avenue, EDGAR, Sale, Suite, Equity capital markets, Sales management, National instrument, ATTN:, Intermediary, Form, NYSE American, Supplement, NYSE, LPC, News, NEO, Security (finance), Property management, Share (finance)

Cybin intends to use the net proceeds from sales of Shares under the ATM Program, if any, for growth opportunities and working capital initiatives.

Key Points: 
  • Cybin intends to use the net proceeds from sales of Shares under the ATM Program, if any, for growth opportunities and working capital initiatives.
  • The ATM Program will be effective until the earlier of the issuance and sale of all of the Shares issuable pursuant to the ATM Program and September 17, 2025 unless earlier terminated in accordance with the terms of the Distribution Agreement.
  • The volume and timing of distributions under the ATM Program, if any, will be determined in Cybin’s sole discretion and in accordance with the Distribution Agreement.
  • The Supplement and accompanying Base Prospectus contain important detailed information about the ATM Program.

SEALSQ Further Expands its North American Footprint by Signing a Distribution Agreement with Symmetry

Retrieved on: 
Monday, July 24, 2023
Berkshire Hathaway, Semiconductor, TTI, Inc., Partnership, Mouser Electronics, Electronics, Internet of things, Symmetry, WIHN, TTI, XTG, Organization, WKEY, Application, Intermediary, Engineering, PKI, Growth, Industrial, Video game

Symmetry’s worldwide sales and engineering team delivers unparalleled technical services to customers and offers an exceptional e-commerce experience.

Key Points: 
  • Symmetry’s worldwide sales and engineering team delivers unparalleled technical services to customers and offers an exceptional e-commerce experience.
  • With its focused line card, growing inventory, and unsurpassed technical support, Symmetry strives to support design engineers and buyers throughout the design cycle and into production.
  • Supported by the strength of Berkshire Hathaway, TTI Inc.’s Family of Specialists includes TTI, XTG, Mouser Electronics, and Sager Electronics.
  • David Khalifa, VP of Global Sales for WISeKey said, “The agreement with Symmetry will expand our customer reach throughout the North American market, specifically on the applications SEALSQ targets such as Smart city, Smart home, Smart appliances or Industrial IoT.

FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders

Retrieved on: 
Friday, June 30, 2023
General Health, Health, Science, Pharmaceutical, Research, Transfer, MNP, Telephone, MNP LLP, AGSM, SEDAR, Intermediary, Remuneration, Security (finance)

Details of Company's report of voting results are available under the Company's profile SEDAR.

Key Points: 
  • Details of Company's report of voting results are available under the Company's profile SEDAR.
  • Shareholders are not required to take any action at this time.
  • If you hold your Class A Shares or Class B Shares with an Intermediary and you have questions in this regard, you are encouraged to contact your intermediary.
  • Shareholders should not destroy any share certificates and should not submit any certificates until requested to do so, if required.

Quipt Home Medical Reports Record Second Quarter Fiscal 2023 Financial Results Posting Revenue Growth of 73% and Adjusted EBITDA Growth of 86%

Retrieved on: 
Tuesday, May 16, 2023
COPD, Standby Equity Distribution Agreement, TSX Venture Exchange, Prevalence, CPAP, Toronto Stock Exchange, Registration statement, Calendar, Great Elm, Peer-to-peer file sharing, EDGAR, Sale, Chronic obstructive pulmonary disease, Register, ATM, EBITDA, Acquisition, Patient, Agent, Intermediary, Indian stock exchange, SEDAR, Distribution, TSX, United, Adjustment, Health, Hand, Conference, Tobacco, Cryptocurrency, Health insurance, Security (finance), Bank, Property management, Canaccord Genuity

Revenues for fiscal Q2 2023 were $58.1 million compared to $33.6 million for fiscal Q2 2022, representing a 73% increase year-over-year.

Key Points: 
  • Revenues for fiscal Q2 2023 were $58.1 million compared to $33.6 million for fiscal Q2 2022, representing a 73% increase year-over-year.
  • Recurring Revenue (defined below) for fiscal Q2 2023 continues to be strong and exceeded 78% of revenues.
  • Adjusted EBITDA (defined below) for fiscal Q2 2023 was $13.1 million (22.5% of revenues), compared to Adjusted EBITDA for fiscal Q2 2022 of $7.0 million (21.0% of revenues), representing an 86% increase year-over-year.
  • For fiscal Q2 2023, bad debt expense was at 4.2% of revenues compared to 9.4% in fiscal Q2 2022.

Capricor Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 11, 2023
Linda, GMP, Commercialization, International, File, CMC, Exosome, ID, Duchenne muscular dystrophy, DMD, Patient, Episcopal conference, MUSCULAR, Intermediary, Distribution, Webcast, Microbiology Spectrum, FDA, Therapy, BLA, Conference, OLE, Pharmaceutical industry, Vaccine

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases, announced today its financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Key Points: 
  • Completed construction of new San Diego GMP manufacturing facility and plan to have commercial-scale GMP CAP-1002 product available in the third quarter of 2023.
  • Presented positive 18-month results from ongoing HOPE-2 OLE study in a late-breaking session at the 2023 MDA Clinical and Scientific Conference.
  • Revenues for the first quarter of 2023 were approximately $3.0 million compared with zero for the first quarter of 2022.
  • Operating expenses: Total operating expenses for the first quarter of 2023 were approximately $11.2 million compared with approximately $7.8 million for the first quarter of 2022.

Innocan Pharma Announces 5000 Units Sale and Expansion to Lithuania, Latvia & Estonia Markets

Retrieved on: 
Monday, May 1, 2023
Standby Equity Distribution Agreement, CSE, Skin care, AB, FSE, USD, UAB, Intermediary, Distribution, CBD, Pharmaceutical industry, Beauty

As part of the multi-year Distribution Agreement, UAB Medexy has an exclusive right to distribute both of Innocan's SHIR™ and RELIEF&GO™ brands in Lithuania, Latvia & Estonia, based on an agreed purchase forecast.

Key Points: 
  • As part of the multi-year Distribution Agreement, UAB Medexy has an exclusive right to distribute both of Innocan's SHIR™ and RELIEF&GO™ brands in Lithuania, Latvia & Estonia, based on an agreed purchase forecast.
  • UAB Medexy's first order under the Distribution Agreement is for over 5000 units of SHIR™ and RELIEF&GO™ products.
  • Innocan Pharma and SHIR™/ RELIEF&GO™ will now be stepping-up to become market leaders in many European countries.
  • Iris Bincovich, CEO of InnoCan stated that "We are humbled to have a leading European market leader such as UAB Medexy as our market-partner in Lithuania, Latvia & Estonia.

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

Retrieved on: 
Friday, April 14, 2023
Standby Equity Distribution Agreement, Intermediary, Patient, Dentistry

Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore.

Key Points: 
  • Ltd. ("Majeton"), has entered into an exclusive Distribution Agreement with Osteopore Limited ("Osteopore") to promote and sell Osteopore's dental and oral maxillofacial products ("Products") in Singapore.
  • Pursuant to the Distribution Agreement, Majeton will be the exclusive distributor of the Products for an initial period of 3 years, starting from 2023 to 2026.
  • Osteopore's innovative oral maxilla facial products are used in guided bone regeneration, immediate implant loading, and socket preservation.
  • In unique situations, Osteopore may also make available customised regenerative implants for various oral maxillofacial reconstruction.

OKX President Hong's HK Web3 Festival Keynote: Crypto is Leading to a Trustless and More Equitable System

Retrieved on: 
Wednesday, April 12, 2023
Bitcoin, Money, Web3, MPC, MH, Hong Kong Monetary Authority, GBM, JP, ETH, Speech, Silicon Valley Bank, Decentralized finance, Fiat, Type, Government, VASP, Silicon, USDT, Reserve, Securities and Futures Commission, OKX, GBS, Growth, Security (finance), Intermediary, BTC, Big Tech, Safety, Cryptocurrency

"Recent events suggest the current system is no longer fit for purpose.

Key Points: 
  • "Recent events suggest the current system is no longer fit for purpose.
  • In response, she called for a trustless system built on blockchain technology and underpinned by real value, greater accessibility as well as transparency.
  • Hong also stated that blockchain technology and the rise of crypto and Web3 are enabling a paradigm shift whereby individuals can become their own bank and platform.
  • The company's efforts in building the rails of a future system through blockchain technology was underlined as well.